GlassScriptPhysician profile
Jose A Diaz
NPI 1578553764
$2,562.17
in general payments reported to CMS, 2019-2025
31 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $283 · 2021: $462 · 2022: $12.06 · 2023: $242 · 2024: $381 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $469.31 | 2019-2025 | Leqvio |
| Janssen Pharmaceuticals, INC | $218.39 | 2019-2024 | Xarelto |
| Medtronic, INC. | $192.23 | 2025 | Attain Command + Surevalve, Micra |
| Philips North America LLC | $157.79 | 2021 | |
| Abiomed | $124.99 | 2024 | Impella |
| Cvrx, INC. | $124.83 | 2024-2025 | Barostim Neo System |
| Mallinckrodt Enterprises LLC | $123.51 | 2019 | |
| Pfizer INC. | $114.69 | 2019-2025 | |
| Amgen INC. | $101.70 | 2019-2020 | |
| Baxter Healthcare | $86.34 | 2019 | |
| Abbott Laboratories | $72.33 | 2021 | |
| Nxstage Medical, INC. | $69.45 | 2019 | |
| Merck Sharp & Dohme LLC | $65.57 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $65.35 | 2019-2025 | Eliquis |
| Amarin Pharma, INC. | $59.60 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $51.76 | 2019-2023 | Entre Plus, Flexitouch Plus |
| Esperion Therapeutics, INC. | $50.22 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $48.97 | 2025 | Qelbree |
| Biocompatibles, INC. | $38.97 | 2019 | |
| Scpharmaceuticals INC. | $38.26 | 2025 | |
| Sanofi-Aventis U.S. LLC | $34.26 | 2019 | |
| Impulse Dynamics (USA) INC. | $34.14 | 2025 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.45 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $31.81 | 2023 | |
| Nalu Medical, INC. | $29.60 | 2025 | Nalu Neurostimulation System |
| Kowa Pharmaceuticals America, INC. | $26.44 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $24.95 | 2024 | |
| Mdd US Operations, LLC | $21.73 | 2025 | Gocovri |
| Bayer Healthcare Pharmaceuticals INC. | $20.57 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.00 | 2024 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $14.96 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.